Preoperative cyclooxygenase-2 inhibitor treatment reduces the incidence of heterotopic ossification after hip arthroplasty: six-month follow-up.
Asokumar
A
Buvanendran
Jeffrey S
JS
Kroin
Richard A
RA
Berger
D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects*; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D015232:Dinoprostone / Q000096:biosynthesis; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006621:Hip Joint / Q000000981:diagnostic imaging; D006801:Humans; D015994:Incidence; D007783:Lactones / Q000627:therapeutic use*; D009999:Ossification, Heterotopic / Q000517:prevention & control*; D011183:Postoperative Complications / Q000517:prevention & control*; D011300:Preoperative Care / Q000379:methods*; D011859:Radiography; D013450:Sulfones / Q000627:therapeutic use*; D015854:Up-Regulation
D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib; D015232:Dinoprostone